Background and Aims: ENHANCEwas a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA).Approach and Results: Patients were randomized 1:1:1 to oral seladelpar 5 mg (n= 89), 10 mg (n= 89), placebo (n= 87) daily (with UDCA, as appropriate). Primary end point was a composite biochemical response [alkaline phosphatase (ALP) < 1.67xupper limit of normal (ULN), >= 15% ALP decrease from baseline, and total bilirubin <= ULN] at month 12. Key secondary end points were ALP normalization at month 12 and change in pruritus numerical rating scale (NRS) at month 6 in patients with baseline score >= 4. Aminotransferases were assessed. ENHANCE was terminated early following an erroneous safety signal in a concurrent, NASH trial. While blinded, primary and secondary efficacy end points were amended to month 3. Significantly more patients receiving seladelpar met the primary end point (seladelpar 5 mg: 57.1%, 10mg: 78.2%) versus placebo (12.5%) (p < 0.0001). ALP normalization occurred in 5.4% (p= 0.08) and 27.3% (p < 0.0001) of patients receiving 5 and 10 mg seladelpar, respectively, versus 0% receiving placebo. Seladelpar 10 mg significantly reduced mean pruritus NRS versus placebo [10 mg: -3.14 (p= 0.02); placebo: -1.55]. Alanine aminotransferase decreased significantly with seladelpar versus placebo [5 mg: 23.4% (p= 0.0008); 10 mg: 16.7% (p= 0.03); placebo: 4%]. There were no serious treatment-related adverse events.Conclusions: Patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus. Seladelpar appeared safe and well tolerated.

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study / Hirschfield, Gideon M; Shiffman, Mitchell L; Gulamhusein, Aliya; Kowdley, Kris V; Vierling, John M; Levy, Cynthia; Kremer, Andreas E; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C; Bowlus, Christopher L; Lawitz, Eric J; Aspinall, Richard J; Pratt, Daniel S; Raikhelson, Karina; Gonzalez-Huezo, Maria S; Heneghan, Michael A; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L; Mayo, Marlyn J; Dalekos, George N; Drenth, Joost P H; Janczewska, Ewa; Leggett, Barbara A; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J; Forman, Lisa; Jones, David E J; Ryder, Stephen D; Swain, Mark G; Steinberg, Alexandra; Boudes, Pol F; Choi, Yun-Jung; Mcwherter, Charles A; Carubbi, F. - In: HEPATOLOGY. - ISSN 0270-9139. - 78:2(2023), pp. 397-415. [10.1097/HEP.0000000000000395]

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Andreone, Pietro;carubbi F
2023

Abstract

Background and Aims: ENHANCEwas a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA).Approach and Results: Patients were randomized 1:1:1 to oral seladelpar 5 mg (n= 89), 10 mg (n= 89), placebo (n= 87) daily (with UDCA, as appropriate). Primary end point was a composite biochemical response [alkaline phosphatase (ALP) < 1.67xupper limit of normal (ULN), >= 15% ALP decrease from baseline, and total bilirubin <= ULN] at month 12. Key secondary end points were ALP normalization at month 12 and change in pruritus numerical rating scale (NRS) at month 6 in patients with baseline score >= 4. Aminotransferases were assessed. ENHANCE was terminated early following an erroneous safety signal in a concurrent, NASH trial. While blinded, primary and secondary efficacy end points were amended to month 3. Significantly more patients receiving seladelpar met the primary end point (seladelpar 5 mg: 57.1%, 10mg: 78.2%) versus placebo (12.5%) (p < 0.0001). ALP normalization occurred in 5.4% (p= 0.08) and 27.3% (p < 0.0001) of patients receiving 5 and 10 mg seladelpar, respectively, versus 0% receiving placebo. Seladelpar 10 mg significantly reduced mean pruritus NRS versus placebo [10 mg: -3.14 (p= 0.02); placebo: -1.55]. Alanine aminotransferase decreased significantly with seladelpar versus placebo [5 mg: 23.4% (p= 0.0008); 10 mg: 16.7% (p= 0.03); placebo: 4%]. There were no serious treatment-related adverse events.Conclusions: Patients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus. Seladelpar appeared safe and well tolerated.
2023
78
2
397
415
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study / Hirschfield, Gideon M; Shiffman, Mitchell L; Gulamhusein, Aliya; Kowdley, Kris V; Vierling, John M; Levy, Cynthia; Kremer, Andreas E; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C; Bowlus, Christopher L; Lawitz, Eric J; Aspinall, Richard J; Pratt, Daniel S; Raikhelson, Karina; Gonzalez-Huezo, Maria S; Heneghan, Michael A; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L; Mayo, Marlyn J; Dalekos, George N; Drenth, Joost P H; Janczewska, Ewa; Leggett, Barbara A; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J; Forman, Lisa; Jones, David E J; Ryder, Stephen D; Swain, Mark G; Steinberg, Alexandra; Boudes, Pol F; Choi, Yun-Jung; Mcwherter, Charles A; Carubbi, F. - In: HEPATOLOGY. - ISSN 0270-9139. - 78:2(2023), pp. 397-415. [10.1097/HEP.0000000000000395]
Hirschfield, Gideon M; Shiffman, Mitchell L; Gulamhusein, Aliya; Kowdley, Kris V; Vierling, John M; Levy, Cynthia; Kremer, Andreas E; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C; Bowlus, Christopher L; Lawitz, Eric J; Aspinall, Richard J; Pratt, Daniel S; Raikhelson, Karina; Gonzalez-Huezo, Maria S; Heneghan, Michael A; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L; Mayo, Marlyn J; Dalekos, George N; Drenth, Joost P H; Janczewska, Ewa; Leggett, Barbara A; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J; Forman, Lisa; Jones, David E J; Ryder, Stephen D; Swain, Mark G; Steinberg, Alexandra; Boudes, Pol F; Choi, Yun-Jung; Mcwherter, Charles A; Carubbi, F
File in questo prodotto:
File Dimensione Formato  
Seladelpar_efficacy_and_safety_at_3_months_in.9.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 2.13 MB
Formato Adobe PDF
2.13 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1319587
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact